EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Deciphering the phenotypic responses to 177Lu-based radioligand therapy to identify efficacious combinations

Marco Ranzani, Alessandro Cicconi, Guillermo Sastre-Moreno, Asmita Thapa, Elise Simon, Josefine Reber, Joseph Barlow, Marie Laure Boursier, Aurora Cerutti, Luisa Deberle, Luigi Del Pozzo, Elias Elinati und 15 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2026

DOI: 10.1007/s00259-026-08092-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Marco Ranzani und 26 weiteren Autor:innen. Beteiligte Einrichtung: Artios Pharma, Babraham Research Campus, Cambridge, UK. Hauptthemen laut MEDLINE: Lutetium, Radioisotopes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LutetiumRadioisotopesHumansCell Line, TumorAnimalsLigandsDNA DamagePhenotypeHeterocyclic Compounds, 1-RingMiceMaleDNA-Activated Protein KinaseCell Survival

Stichwörter der Autor:innen

DNA damage responseDNA-PK inhibitorDouble-strand break repairNon-homologous end joiningRadioligand therapy[177Lu]Lu-PSMA-617

Substanzen

LutetiumLutetium-177RadioisotopesLigandsHeterocyclic Compounds, 1-RingDNA-Activated Protein Kinase

Autor:innen und Institutionen

  • Artios Pharma, Babraham Research Campus, Cambridge, UK.
  • Novartis Biomedical Research, Disease Area Oncology, Basel, Switzerland.
  • Artios Pharma, Babraham Research Campus, Cambridge, UK. hrobinson@artios.com.
  • Novartis Biomedical Research, Disease Area Oncology, Basel, Switzerland. marta.cortes-cros@novartis.com.

Zitieren

APA

Ranzani, M., Cicconi, A., Sastre-Moreno, G., Thapa, A., Simon, E., Reber, J., Barlow, J., Boursier, M. L., Cerutti, A., Deberle, L., Del Pozzo, L., Elinati, E., Geo, L., Grinkevich, V., Hartnagel, C., Hindupur, S. K., Koler, K., Menon, S., Neves, J., …, & Cortes-Cros, M. (2026). Deciphering the phenotypic responses to 177Lu-based radioligand therapy to identify efficacious combinations. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08092-x

Vancouver

Ranzani M, Cicconi A, Sastre-Moreno G, Thapa A, Simon E, Reber J, et al. Deciphering the phenotypic responses to 177Lu-based radioligand therapy to identify efficacious combinations. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-08092-x

BibTeX
@article{Ranzani2026,
  author = {Ranzani, Marco and Cicconi, Alessandro and Sastre-Moreno, Guillermo and Thapa, Asmita and Simon, Elise and Reber, Josefine and Barlow, Joseph and Boursier, Marie Laure and Cerutti, Aurora and Deberle, Luisa and Del Pozzo, Luigi and Elinati, Elias and Geo, Lerin and Grinkevich, Vera and Hartnagel, Charlene and Hindupur, Sravanth K and Koler, Katjusa and Menon, Suraj and Neves, Joana and Schacher, Barbara and Shao, Nan and Rajendra, Eeson and Reschke, Markus and Schmelzle, Tobias and Smith, Graeme C M and Robinson, Helen M R and Cortes-Cros, Marta},
  title = {Deciphering the phenotypic responses to 177Lu-based radioligand therapy to identify efficacious combinations},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  doi = {10.1007/s00259-026-08092-x}
}
Kostenlos starten →